Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224822 · ClinicalTrials.gov registry record · Phase 4
The Effects of Aripiprazole on Patients With Metabolic Syndrome
A Phase 4 study, sponsored by New Mexico VA Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00224822 is a Phase 4 study that has completed, run by New Mexico VA Healthcare System. The registered enrollment target is 27 participants.
The verdict
NCT00224822, a Phase 4 study, has completed, sponsored by New Mexico VA Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224822
The ClinicalTrials.gov registry entry for NCT00224822 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico VA Healthcare System, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00224822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224822 about?
NCT00224822 is a clinical study titled "The Effects of Aripiprazole on Patients With Metabolic Syndrome". The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.
What is the current status of trial NCT00224822?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2004-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00224822?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00224822?
This trial is sponsored by New Mexico VA Healthcare System, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.